Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

A taste of five new restaurants on Franklin Street
One40 Social brings a new energy to the sports bar scene on Franklin Street, complete with plenty of giant TVs, games and upbeat music. It...
Wed Oct 22, 2025

UNC Researcher Earns MacArthur ‘Genius’ Grant to Support Work Preventing Drug Overdoses
Nabarun Dasgupta, an epidemiologist and researcher with UNC’s Gillings School of Public Health, is the latest Chapel Hill faculty member to earn a MacArthur Foundation...
Tue Oct 21, 2025

Video: Carolina Insider - Interview With Former Denver Nuggets Coach and Tar Heel Dad Michael Malone
Former Denver Nuggets Head Coach, Michael Malone, also a proud UNC Volleyball parent, joins Jones Angell and Adam Lucas to talk about what it took...
Mon Oct 20, 2025

A statue to honor Marty Brennanan – and an era of baseball that's gone forever
Even the clouds knew it was a special day in Cincinnati. Right on cue, they parted above the riverfront, and sunlight flooded into the crowd...
Sun Oct 19, 2025